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Summary: Purpose: Oxcarbazepine (OZC) is a second-
generation antiepileptic drug (AED) that also may be used as
a mood stabilizer. Unlike carbamazepine (CBZ), which is an
inducer of the cytochrome P-450 isoforms and may acceler-
ate the elimination of several therapeutic agents, OXC seems
to have only a modest inducing action. The aim of this inves-
tigation was to evaluate the effect of a treatment with OXC on
plasma concentrations of the new antipsychotics risperidone and
olanzapine.
Methods: OXC, at a dosage of 900–1,200 mg/day, was admin-
istered for 5 consecutive weeks to 25 outpatients, 10 men and
15 women, aged 25 to 64 years, with bipolar or schizoaffective
disorder. Twelve patients were stabilized on risperidone therapy
(2–6 mg/day) and 13 on olanzapine (5–20 mg/day). Steady-state
plasma concentrations of risperidone and its active metabolite
9-hydroxyrisperidone (9-OH-risperidone) and olanzapine were
measured by high-pressure liquid chromatography (HPLC) be-
fore addition of OXC and after 5 weeks from the start of adjunc-
tive treatment.
Results: OXC caused only minimal and no significant changes
in the mean plasma levels of risperidone (from 5.6 ± 3.6 ng/ml at
baseline to 4.8 ± 2.6 ng/ml at week 5), 9-OH-risperidone (from
23.6 ± 7.5 to 24.7 ± 7.4 ng/ml), and olanzapine (from 26.5 ± 5.7
ng/ml at baseline to 27.8 ± 5.1 ng/ml). OXC coadministration
with either risperidone or olanzapine was well tolerated.
Conclusions: Our findings indicate that OXC does not af-
fect the elimination of risperidone and olanzapine, thus con-
firming its weak inducing effect on hepatic drug-metabo-
lizing enzymes.
Psychiatry comorbidity with epilepsy is common and
often requires the combined use of psychotropic drugs and
antiepileptic drugs (AEDs). Moreover, a number of AEDs
are increasingly used in the management of psychiatric
disorders, generally as mood stabilizers and often in com-
bination with antidepressants, lithium, or antipsychotics.
As many AEDs and psychotropics influence the activity
of the hepatic drug-metabolizing enzymes, the possibility
of pharmacokinetic interactions between these drugs must
be taken into account (1).
Oxcarbazepine (OXC), a keto-analog of carbamazepine
(CBZ), is a relatively new AED with mood-stabilizing
properties (2). Although structurally related to CBZ, OXC
has a different metabolic profile. In particular, its bio-
transformation does not lead to formation of CBZ-10,11-
epoxide with subsequent advantages in terms of tolera-
bility. Conversely, OXC undergoes rapid and extensive
reduction to a major active metabolite, 10-monohydroxy
derivative (MHD) or licarzepine (approved chemical
name), by a noninducible cytosol arylketone reductase (3).
The formation of MHD from OXC is stereoselective with
S-MHD being the major metabolite (3). OXC acts in hu-
mans mainly through MHD, and only minimal amounts of
the parent drug are found in peripheral blood (3). Unlike
CBZ, which is an inducer of different cytochrome P-450
(CYP) enzymes (4), OXC seems to have only a modest
inducing action, possibly more evident at high doses or re-
lated to induction of specific CYP isoforms such as those
involved in the metabolism of oral contraceptives (5) and
calcium antagonist felodipine (6).
Risperidone and olanzapine are newer atypical antipsy-
chotics widely used in the treatment of schizophrenia and
bipolar disorder. Risperidone is extensively metabolized
in the liver mainly by 9-hydroxylation, resulting in the
formation of a chiral carbon atom yielding two enan-
tiomers (7). This reaction is catalyzed by CYP2D6 and,
to a lesser extent, by CYP3A4 (7,8). The major metabolic
pathways of olanzapine include direct N-glucuronidation,
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mediated by uridine diphosphate glucuronyltransferase
(UDPGT), and N-demethylation, mediated by CYP1A2
(8). Although animal models show no in vivo activity
for the metabolites of olanzapine, the major oxidative
metabolite of risperidone, 9-hydroxyrisperidone (9-OH-
risperidone), is pharmacologically active and may there-
fore contribute to the clinical effects of the parent drug (8).
It is well documented that concomitant administration of
other compounds, acting as inhibitors or inducers of CYP
enzymes involved in antipsychotic metabolism, may affect
their plasma concentrations with potential clinical impli-
cations (8).
To investigate the interaction between OXC and the
novel antipsychotics risperidone and olanzapine, we car-
ried out drug monitoring of plasma concentrations of
risperidone, 9-OH-risperidone, and olanzapine in patients
with bipolar or schizoaffective disorder given OXC as a
mood stabilizer to control aggressive symptoms in addi-
tion to an ongoing antipsychotic regimen.
PATIENTS AND METHODS
Patients and study procedures
Twenty-five outpatients (10 men and 15 women, aged
25 to 64 years) participated in the study. They had a di-
agnosis of bipolar (n = 14) or schizoaffective (n = 11)
disorder, according to the Diagnostic and Statistical Man-
ual of Mental Disorders, 4th edition (DSM-IV), and were
stabilized on risperidone (n = 12) or olanzapine (n = 13)
therapy but required treatment with a mood stabilizer. The
protocol was approved by a local Ethics Committee, and
written informed consent was obtained from the patients or
their relatives. All patients had been treated with risperi-
done, at a dosage of 2–6 mg/day (given as two divided
daily administrations), or olanzapine, 5–20 mg/day (ad-
ministered once daily at bedtime), for ≥2 months without
changes in dosage over the previous month. They received
adjunctive OXC at the initial dose of 300 mg/day, which
was then increased to 900–1,200 mg/day by the end of
week 1 and maintained constant for the next 4 weeks. The
dosage and frequency of risperidone or olanzapine admin-
istration also were kept constant throughout the duration of
the study, and use of other drugs known to act as inhibitors
or inducers of risperidone or olanzapine metabolism was
not allowed (8). Concomitant treatment with other medi-
cation, when present, also remained unchanged.
Blood samples for pharmacokinetic evaluations were
drawn into heparinized tubes at 8 AM, immediately before
the OXC and antipsychotic morning dose, in the week
before starting OXC (baseline) and after 5 weeks of OXC
coadministration. The plasma was separated immediately
and stored at –20◦C until assayed.
Drug assays
Steady-state plasma concentrations of risperidone and
9-OH-risperidone were measured by HPLC according to
the method of Avenoso et al. (9). The limit of quantifi-
cation of the assay was 2 ng/ml for both analytes. The
assay for 9-OH-risperidone was not stereoselective. How-
ever, as no available information exists about differences
in the pharmacologic activity of the two enantiomers (7),
the use of a nonstereospecific assay may be appropriate.
Plasma concentrations of olanzapine were estimated by
the HPLC method of Boulton et al. (10). The lowest limit
of quantification was 5 ng/ml. As a measure of compli-
ance, the plasma concentrations of MHD were assayed by
the same method used for determination of risperidone,
slightly modified to allow coextraction of MHD. Details
of this procedure will be described elsewhere. The limit
of quantification was 1 µg/ml.
Statistical analysis
Plasma concentrations of risperidone, 9-OH-
risperidone, and their sum (active moiety) and plasma
concentrations of olanzapine before and during OXC
administration were compared by Student’s t test for
paired data. Linear regression analysis was used for
correlation of plasma concentrations of risperidone,
9-OH-risperidone, and olanzapine at baseline and at
week 5. Results are given in the text as mean ± SD,
together with 95% confidence interval (CI) for the mean
differences. A p value <0.05 was regarded as statistically
significant.
RESULTS
Demographic and clinical characteristics of patients
participating in the study and mean steady-state plasma
concentrations of risperidone, 9-OH-risperidone, risperi-
done active moiety, and olanzapine before and after 5
weeks of OXC administration are reported in Table 1. OXC
caused no significant changes in the mean plasma levels
of risperidone (from 5.6 ± 3.6 ng/ml at baseline to 4.8 ±
2.6 ng/ml at week 5; mean difference, 0.7; 95% CI, −0.4
to 1.9) and metabolically derived 9-OH-risperidone (from
23.6 ± 7.5 to 24.7 ± 7.4 ng/ml; mean difference, −1.1;
95% CI, −3.8 to 1.7), so that the risperidone active moi-
ety remained unchanged (from 29.2 ± 10.2 to 29.5 ± 9.0
ng/ml; mean difference, −0.3; 95% CI, −3.4 to 2.8). Simi-
larly, the mean plasma concentrations of olanzapine were
not significantly modified during OXC treatment (from
26.5 ± 5.7 ng/ml at baseline to 27.8 ± 5.1 ng/ml at week
5; mean difference, −1.4; 95% CI, −4.3 to 1.6). A sta-
tistically significant intraindividual correlation between
plasma levels at baseline and at week 5 was found for
risperidone (r = 0.87; p < 0.001), 9-OH-risperidone (r
= 0.83; p < 0.001) and olanzapine (r = 0.78; p < 0.01).
Plasma concentrations of MHD at week 5 ranged from 2.9
to 28.7 µg/ml.
Concomitant treatment of OXC with either risperi-
done or olanzapine was well tolerated, and no symp-
toms of antipsychotic toxicity were reported throughout
TABLE 1. Demographic and clinical data of patients participating in the study and steady-state
plasma concentrations of risperidone, 9-OH-risperidone, risperidone active moiety, and olanzapine
before and after 5 weeks of oxcarbazepine administration
Risperidone group (n = 12) Olanzapine group (n = 13)
Sex Sex
Men: 3, Women: 9 Men: 7, Women: 6
Age (yr) Age (yr)
Mean ± SD (range): 39.4 ± 10.1 (27–54) Mean ± SD (range): 44.1 ± 12.2 (25–64)
Risperidone dose (mg/day) Olanzapine dose (mg/day)
Mean ± SD (range): 3.2 ± 1.1 (2–6) Mean ± SD (range): 10.4 ± 3.8 (5–20)
Oxcarbazepine dose (mg/day) Oxcarbazepine dose (mg/day)
Mean ± SD (range): 1,050 ± 157 (900–1,200) Mean ± SD (range): 1,108 ± 144 (900–1,200)
Risperidone concentrations (ng/ml) Olanzapine concentrations (ng/ml)
Baseline mean ± SD (range): 5.6 ± 3.6 (2–16) Baseline mean ± SD (range): 26.5 ± 5.7 (14–39)
Week 5 mean ± SD (range): 4.8 ± 2.6 (2–11) Week 5 mean ± SD (range): 27.8 ± 5.1 (21–38)
Mean difference: 0.7; 95% CI: −0.4 to 1.9 Mean difference: −1.4 95%; CI: −4.3 to 1.6
p Value: 0.19 p Value: 0.38
9-Hydroxyrisperidone concentrations (ng/ml) MHD concentrations (µg/ml)
Baseline mean ± SD (range): 23.6 ± 7.5 (11–41) Mean ± SD (range): 15.0 ± 7.3 (3.7–28.7)
Week 5 mean ± SD (range): 24.7 ± 7.4 (13–36)
Mean difference: −1.1; 95% CI, −3.8 to 1.7
p Value: 0.40
Risperidone active moiety concentrations (ng/ml)
Baseline mean ± SD (range): 29.2 ± 10.2 (14–57)
Week 5 mean ± SD (range): 29.5 ± 9.0 (15–47)
Mean difference: −0.3; 95% CI, −3.4 to 2.8
p Value: 0.82
MHD concentrations (µg/ml)
Mean ± SD (range): 13.9 ± 6.5 (2.9–22.4)
95% CI, 95% confidence interval for the mean differences.
the observation period. During the first few days of OXC
administration, some patients (three) complained of seda-
tion, headache (two), dizziness (two), and fatigue (one).
These complaints were generally mild and decreased in in-
tensity during the further course of the treatment period.
DISCUSSION
In view of the increasing use of AEDs, particularly
those with mood-stabilizing properties, in combination
with new antipsychotics, the possibility of a pharmacoki-
netic interaction between these compounds should be in-
vestigated.
The results of the present study indicate that OXC does
not affect the elimination of the newer atypical antipsy-
chotic risperidone and olanzapine. A 5-week adminis-
tration of therapeutic doses of OXC to 25 patients with
bipolar or schizoaffective disorder, stabilized on risperi-
done (12 patients) or olanzapine (13 patients), caused
only minimal and not significant modifications in steady-
state plasma concentrations of risperidone and its active
metabolite as well as in plasma concentrations of olanza-
pine. To the best of our knowledge, this is the first docu-
mentation of the effect of OXC on plasma concentrations
of these two antipsychotics.
The lack of a significant pharmacokinetic interaction
between OXC and risperidone or olanzapine observed in
our patients indicates that this agent minimally affects the
activity of the enzymes involved in the metabolism of these
antipsychotics, thus confirming its weak inducing capac-
ity (11). Conversely, its congener CBZ markedly induces
the activity of various CYP isoforms and, possibly, glu-
curonidating enzymes and has been reported to decrease
plasma concentrations of various antipsychotics signifi-
cantly (1,4). In this respect, different studies have docu-
mented that CBZ may cause a considerable decrease (by
∼30–70%) of plasma concentrations of both risperidone
(12) and olanzapine (13), presumably through induction
of CYP3A4 (risperidone) and CYP1A2 and/or UDPGT
(olanzapine). In a case study, the marked decrease in the
plasma levels of risperidone active fraction after addition
of CBZ was associated with an acute exacerbation of psy-
chotic symptoms (14).
Concomitant administration of OXC with newer an-
tipsychotics was well tolerated, and only few patients de-
veloped mild and transient OXC-related side effects dur-
ing the first few days after its addition. Moreover, OXC
augmentation was associated with no worsening in psy-
chotic symptoms.
In conclusion, despite some methodologic limitations
such as the relatively small sample size and the open de-
sign, the results of this study confirm that OXC has a low
potential for metabolically based drug interactions and
suggest that this agent, unlike CBZ, may be added safely
to patients receiving maintenance treatment with risperi-
done or olanzapine. Admittedly, this study was performed
in patients with psychiatric disorders, but its implications
for the treatment of patients with epilepsy and associated
psychosis are quite obvious. In this respect, different from
clozapine and many conventional antipsychotics (i.e., phe-
nothiazines), which may reduce the seizure threshold,
risperidone and olanzapine appear to have a low procon-
vulsive risk (15).
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